Home › Funds › Conestoga Capital Advisors, LLC › RGEN

Conestoga Capital Advisors, LLC position in RGEN

Repligen Corp · Health Care

Conestoga Capital Advisors, LLC reported holding 700,626 shares of RGEN (Repligen Corp) in its Q3 2026 13F filing — a position valued at US$134.7M, representing 4.07% of its reported portfolio and ranking #3 among its reported holdings. Conestoga Capital Advisors, LLC has disclosed RGEN holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)700.63K sh
Reported value held$134.68M
Portfolio Weight4.07%
First reportedQ3 2023
Last changeReduce
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How Conestoga Capital Advisors, LLC's RGEN position evolved

Conestoga Capital Advisors, LLC first disclosed a stake in RGEN in Q3 2023 at 707,148 shares (US$112.4M). The position peaked in Q4 2025 at 1,057,975 shares, worth US$173.4M. Across 13 filings, Conestoga Capital Advisors, LLC increased the stake 6 time(s), trimmed it 4 time(s) and left it unchanged 2 time(s). The most recent filing (Q3 2026) shows 700,626 shares valued at US$134.7M — a reduction of -280,357 shares quarter over quarter.. Notable position changes include a 27% increase in Q2 2024 (shares rose 18% over the following quarter), a 29% trim in Q3 2026 (shares fell 10% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 707.15K $112.44M New
Q4 2023 709.74K $127.61M Hold
Q1 2024 747.55K $137.49M Add
Q2 2024 946.88K $119.36M Add
Q3 2024 940.71K $140.00M Reduce
Q4 2024 947.58K $136.39M Add
Q1 2025 980.25K $124.73M Add
Q2 2025 976.91K $121.51M Hold
Q3 2025 956.91K $127.91M Reduce
Q4 2025 1.06M $173.36M Add
Q1 2026 1.10M $129.34M Add
Q2 2026 980.98K $133.85M Reduce
Q3 2026 700.63K $134.68M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About RGEN and 13F data

RGEN (Repligen Corp) is a Health Care company. 32 other funds we track also report a position in RGEN — the largest reported positions include UNITED CAPITAL FINANCIAL ADVISORS, LLC (US$536.3M), Maverick Capital (US$270.8M), MAVERICK CAPITAL LTD (US$270.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding RGEN

All RGEN fund holders →

FAQ

How long has Conestoga Capital Advisors, LLC held RGEN?

Conestoga Capital Advisors, LLC has disclosed RGEN holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is Conestoga Capital Advisors, LLC's current position in RGEN?

As of Q3 2026, Conestoga Capital Advisors, LLC holds 700.63K shares of RGEN (Repligen Corp), valued at $134.68M, representing 4.07% of its reported portfolio and ranking #3.

Has Conestoga Capital Advisors, LLC been buying or selling RGEN?

In the latest 13F filing (Q3 2026), Conestoga Capital Advisors, LLC reduced its position in RGEN. The position peaked in Q4 2025 at 1.06M shares.

Which other funds hold RGEN?

Other major institutional holders of RGEN include UNITED CAPITAL FINANCIAL ADVISORS, LLC, Maverick Capital, MAVERICK CAPITAL LTD, among 32 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.